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Summary. The incidence of acute biphenotypic leukaemia 
has ranged from less than 1% to almost 50% in various 
reports in the literature. This wide variability may be 
attributed to a number of reasons including lack of consistent 
diagnostic criteria, use of various panels of antibodies, and 
the failure to recognize the lack of lineage specificity of some 
of the antibodies used. The morphology, cytochemistry, 
immunophenotype and cytogenetics of acute biphenotypic 
leukaemias from our institution were studied. The diagnostic 
criteria took into consideration the morphology of the 
analysed cells, light scatter characteristics, and evaluation of 
antibody fluorescence histograms in determining whether 
the aberrant marker expression was arising from leukaemic 
blasts or differentiated bone marrow elements. Fifty-two of 
746 cases (7%) fulfilled our criteria for acute biphenotypic 
leukaemias. These included 30 cases of acute lymphoblastic 
leukaemia (ALL) expressing myeloid antigens, 2 1 cases of 
acute myelogenous leukaemia (AML) expressing lymphoid 
markers, and one case of ALL expressing both B- and T-cell 
associated antigens. The acute biphenotypic leukaemia cases 
consisted of four major immunophenotypic subgroups: 
CD2f AML (11), CD19+ AML (8), CD13 and/or CD33+ 
ALL (24), C D l l b +  ALL (5) and others (4). Chromosomal 
analysis was carried out in 42/52 of the acute biphenotypic 
leukaemia cases: a clonal abnormality was found in 31 of 
these 42 cases. This study highlights the problems encoun- 
tered in the diagnosis of acute biphenotypic leukaemia, some 
of which may be reponsible for the wide variation in the 
reported incidence of this leukaemia. We suggest that the use 
of strict, uniform diagnostic criteria may help in establishing 
a more consistent approach towards diagnosis of this leukae- 
mic entity. We also suggest that biphenotypic leukaemia is 
comprised of biologically different groups of leukaemia based 
on immunophenotypic and cytogenetic findings. 
The classification of acute leukaemia has traditionally been 
based on a combination of morphology and cytochemical 
staining. These diagnostic modalities are quite sufficient to 
accurately classify the majority of acute leukaemias. Flow 
cytometric immunophenotyping has also evolved as an 
important laboratory tool to be used in the diagnosis and 
classification of acute leukaemia. By using monoclonal 
antibodies reactive against various lymphoid- or myeloid- 
associated antigens, it is possible to distinguish acute lympho- 
blastic leukaemia from acute myelogeneous leukaemia and 
to identify subsets within each of the respective acute 
leukaemias. In addition, immunophenotyping studies have 
given us insight into the immunologic sequence of normal 
lymphoid and myeloid ontogeny (LeBien & Villablanca, 
1990; Terstappen & Loken, 1990). 
Considerable interest has developed over the last decade in 
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those acute leukaemias that have immunophenotypes that 
do not fit into the accepted sequence of normal lymphoid or 
myeloid cell development (Perentesis et al, 1983; Mirro et al, 
1985, 1986; Stass & Mirro, 1985; Drexler et al, 1986; 
Campos et al. 1987; Cross et al, 1988; Schmitt-Graff et al, 
1988; Del Vecchio et al. 1989; Kaplan et al. 1989: Akashi et 
al, 1990; Gerhartz & Schmetzer, 1990; Sulak et al, 1990). 
Perhaps the most controversial and confusing of these 
immunologically aberrant cases have been the so-called 
acute biphenotypic leukaemias. A plethora of terminologies 
(hybrid, mixed-lineage, bilineal, biclonal, biphenotypic) has 
added to the confusion in this area (Gale & Ben-Bassat, 198 7; 
Maitreyan & Gale, 1989). Such phenotypes imply that either 
malignant transformation leads to aberrant gene expression 
(‘lineage infidelity’) (Smith et al, 1983) or that co-expression 
of ‘lineage-specific’ markers occurs normally in differentia- 
tion of haematopoietic cells (‘lineage promiscuity’) (Greaves 
& Chan, 1986; Greaves et al, 1986). The clinical significance 
of biphenotypia in acute leukaemia has not been determined, 
as such studies have suffered from the lack of consistent 
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guidelines for classification. Some studies have suggested that 
biphenotypic leukaemias have a worse clinical prognosis 
than non-biphenotypic acute lymphoblastic leukaemia or 
acute myelogenous leukaemia, while other reports have not 
confirmed that clinical significance exists (Sobol et al, 1987; 
Ferrara et al, 1990; Pui et al, 1990; Bal et al, 1991; Wiersma 
rt 01, 1991). 
This report describes 52 patients with acute biphenotypic 
leukaemia out of a cohort of 746 patients. The incidence of 
biphenotypia (7.0%) in this study is lower than some studies 
in the literature have suggested, bringing into question the 
various criteria that have been used for the diagnosis of 
biphenotypic leukaemias. The 52 biphenotypic cases in this 
study are subcategorized into various immunophenotypic 
subgroups, which may prove helpful in understanding the 
biological sequence of haematopoietic development. Cytoge- 
netic studies reveal a variety of chromosomal aberrations, in 
addition to the commonly reported t(9;22) and l l q 2 3  
abnormalities (Hirsch-Ginsberg et al, 1988; Childs et al, 
1988: Hayashi et al, 1990a, b). These cytogenetic studies are 
essential in characterizing these intriguing leukaemias and 
may provide additional diagnostic and biological informa- 
tion. 
MATERIALS AND METHODS 
Patient population. The case population for this study was 
derived from 746 specimens of adult and paediatric acute 
leukaemia analysed at the University of Michigan Flow 
Cytometry Laboratory from January 1985 to December 
1990. A diagnosis of acute leukaemia was established using 
the morphologic and cytochemical criteria of the French- 
American-British (FAB) cooperative group. Cytologic fea- 
tures were assessed on Wright-Giemsa-stained smears of 
bone marrow and/or peripheral blood. Cytochemical stains, 
including myeloperoxidase, Sudan black B, and alpha- 
naphthyl butyrate esterase (non-specific esterase), were used 
to sub-classify the acute myelogenous leukaemia cases. 
Clinical information including age, sex, and mode of presen- 
tation (i.e., de novo versus relapse), was determined from data 
available to the laboratory. 
Monoclonal antibodies. Surface immunophenotyping of 
leukaemic cells was performed by flow cytometry with the 
use of a broad panel of lymphoid- and myeloid-associated 
monoclonal antibodies (MoAbs). These included: B-cell asso- 
ciated MoAbs (CD19, CD20, CD22): T-cell-associated MoAbs 
(CDI, CD2, CD3, CD4, CD5, CD7, CD8); myeloid-associated 
MoAbs (CDllb, CD13, CD14. CD33); and non-lineage 
specific MoAbs (CDIO, CD34 and HLA-DK). 
Plow cytornetricprocedure.. Mononuclear cells were isolated 
from heparinized blood and/or bone marrow specimens by 
standard Ficoll-Hypaque density gradient centrifugation. A 
Wright-Giemsa-stained cytocentrifuge preparation of the 
Ficoll-Hypaque-separated mononuclear cells was morpholo- 
gically evaluated in each case. The percentage of blasts was 
determined on this preparation to evaluate the effectiveness 
of the gradient separation and to aid in the subsequent setting 
of light scatter gates. The mononuclear cells were analysed by 
either an Epics V or Profile Flow Cytometer (Coulter Corpora- 
tion, Hialeah, Fla.); 5000-10000 cells were analysed for 
each MoAb that was used. The mononuclear cells were then 
divided into 'electronic gates' based on the forward angle and 
90" light scatter characteristics of the various cell popula- 
tions (Ross et al, 1990). Single-parameter, fluorescence 
histograms were then generated with each antibody for each 
of the gated cell populations. The percentage of cells positive 
for each marker was calculated by a normalized subtraction 
computer analysis program (IMMUNO; Coulter Corporation; 
Hialeah, Fla.) to account for the background and non-specific 
staining seen with an immunoglobulin isotype-matched 
negative control (Bagwell, 1989). Two-colour, direct im- 
munofluorescent staining was performed in a limited number 
of cases using either a Profile or FACScan flow cytometer 
(Becton-Dickinson Corporation, Mountainview, Calif.). Inter- 
pretation of dual staining was based on simultaneous 
presence of red and green fluorescence. 
Criteria for biphenotypic diagnosis. Biphenotypia was defined 
in this study as expression on leukaemic blasts of at least one 
lymphoid- and at least one myeloid-associated epitope. The 
diagnosis and identification of the acute biphenotypic leukae- 
mias was a multi-step process based on various criteria. First, 
retrospective screening of a computer database was done to 
identify leukaemic cases that had greater than 15% positivity 
with at least one myeloid-associated (CD1 Ib, CDl3, CD14 or 
CD33) and one lymphoid-associated (CDI, CD2, CD3, CD5, 
CD8, CD19 or CD20) MoAb. CD4, CD7, CDlO and CD34 were 
not used as lineage-specific markers, as those antigens are 
commonly found in both lymphoid and myeloid cells (Han- 
son & Gajl-Peczalska, 1988). The percentage ofpositivity was 
not the sole criterion used to define biphenotypia. This liberal 
screening threshold was selected to ensure that no potential 
cases were excluded. 131 cases were identified from the 
database by this initial screen. 
All cases selected by this initial screen were then further 
evaluated for evidence of biphenotypia, using various mor- 
phologic and flow cytometric-derived criteria. These more 
strict criteria were used to address two issues: (1) to allow the 
consistent separation of leukaemic blasts from mature lym- 
phocytes or differentiating myeloid (leukaemic or normal) 
cells based on a combination of flow cytometric light scatter 
characteristics, morphologic correlates, and percentages of 
antibody positivity: and (2) to allow the accurate determina- 
tion of 'true' antigenic staining separate from non-specific 
background reactivity. This process included evaluation of 
the differential cell count to identify the types of cells being 
analysed by the flow cytometer. Light scatter (forward angle 
versus 90" angle) characteristics were then used to establish 
electronic gates around the cell populations of interest. The 
resulting light scatter gates were correlated with the cytocen- 
trifuge preparation differential in an attempt to determine 
which morphologic subsets were present in the respective 
gated areas. The light scatter distributions from these cases 
were also categorized according to the number of gated 
populations and whether the morphologic correlation sug- 
gested the presence of either a uniform population of blasts or 
mixtures of blasts and non-malignant cells in each of the 
gated areas. 
To distinguish mature lymphoid cells from blasts, the 
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finding of equal numbers of cells expressing multiple, pan-T- 
cell antigens (CD2, CD3, CD5, CD7 and CD4 and/or CD8) and 
the presence of comparable numbers of small lymphocytes on 
the differential count of gradient-separated cells were used as 
evidence that ‘contaminating’ lymphoid cells were in the 
leukaemic blast gate. A similar process was used to evaluate 
the possibility of differentiated myeloid cells contaminating 
the leukaemic blast gate. 
The computer analysis program was used to subtract non- 
specific background staining from true antigenic staining; 
this was, as expected, more of a problem in AML than in ALL 
cases. Computer programs for histogram analysis, whether 
based on simple integration or a subtraction algorithm, 
involve arbitrary settings of analytic parameters. Because of 
these arbitrary rules, falsely low or high percentages can be 
generated (Bagwell, 1989). Thus, it is essential to subjecti- 
vely evaluate the flow cytometric histograms in comparison 
with the background reactivity to determine whether the 
calculated percentage of positivity accurately reflects the 
staining contribution of the negative control. If this evalu- 
ation suggested that the calculated percentages were in error, 
then a subjective determination was made as to whether or 
not the particular antigen in question was indeed being 
identified on the leukaemic cells. 
Statistics. Statistical comparisons between the biphenoty- 
pic leukaemias and nonbiphenotypic leukaemias were per- 
formed using either the Student t or Chi square analyses. 
Cgtogenetics. Heparinized bone marrow aspirates were 
cultured at 37°C at an approximate concentration of 10‘ 
cells/ml for 2, 24  or 48 h in RPMI 1640 medium supple- 
mented with 10% heat-inactivated fetal calf serum, penicillin 
and streptomycin. When sufficient specimen was available, 
duplicate cultures were established for 24-48 h synchroniza- 
tion using fluorodeoxyuridine. Cells were arrested in meta- 
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phase with colcemid, harvested, and fixed: slides were 
prepared using standard cytogenic techniques (Sheldon & 
Nichols, 1981). Trypsin-Giemsa banding was used. A mini- 
mum of 20 cells were analysed in the majority of cases. 
Cytogenetic findings were described using the International 
Standards for Cytogenic Nomenclature (ISCN) nomenclature 
(Harnden & Klinger, 1985). 
RESULTS 
fncidencelexclided cases 
The Flow Cytometry Laboratory analysed 746 cases of acute 
leukaemia between the years 1985 and 1990. 131 cases 
were identified on our initial screen for biphenotypia based 
solely on percentage (> 15%) of antibody positivity. Seventy- 
nine of these 131 cases were not included in our final 
biphenotypic group: 50 of these were acute myelogenous 
leukaemias (AML) and 29 were acute lymphocytic leukae- 
mias (ALL). The percentage of blasts on the cytocentrifuge 
preparation of those cases ranged from 25% to 100% with a 
median of 72% blasts. The remaining 52 cases (7.0%) fulfilled 
our criteria for biphenotypic leukaemia; 2 1 were AML and 3 1 
were ALL. The blast percentage on the cytocentrifuge 
preparation in the biphenotypic cases ranged from 26% to 
100% with a median of 76%; 10 cases had less than 50% 
blasts. 
Four basic light scatter patterns emerged when analysing 
the leukaemic specimens of both the biphenotypic cases and 
the cases excluded from the study: (1) a single uniform 
population composed entirely of leukaemic blasts; (2) a single 
population composed of a mixture of blasts and lymphocytes 
and/or differentiated myeloid cells: ( 3 )  two or more distinct 
populations, in which one uniform blast population could be 
clearly separated from normal lymphocytes or differentiated 
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Fig 1.  (A) A dot plot of forward scatter (FS) and orthogonal scatter (LSS) of an acute biphenotypic leukaemia with a single light scatter population 
[patterns ( 1 )  and ( 2 )  from text]. The rectangle around the cell cluster is machine-generated. (B) A dot plot of forward scatter (FS) and orthogonal 
scatter (LSS) of an acute biphenotypic leukaemia with two light scatter populations [patterns (3)  and (4) from text]. A higher percentage of cells is 
seen in the population with low forward and orthogonal scatter. The rectangle is machine-generated, while the ellipse is operator-generated. 
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Table I. Clinical features. 
AML (n=21) ALL (n=31)  Total ( 1 1 ~ 5 2 )  




9-1 8 3 





De novo 18 






















Table 11. Lymphoid antigen-positive AML (n= 21) 
CD2+ (n=11) CD19f (n=8) CD20+ (n=2) 
Age (years) 
1-8 0 2 0 
9-18 2 1 0 
> 18 9 5 2 
FAB 
M1 0 0 0 
M2 0 6 0 
M3 2 1 0 
M4 4 0 0 
M5 2 1 2 
M6 0 0 0 
M7 0 0 0 
Presentation 
De novo 8 8 2 
Relapse 0 0 0 
Blast crisis 3 0 0 
Positivity 
Range (%) 34-78 42-80 28-64 
Median(%) 56 52 46 
myeloid cells: and (4) two or more light scatter populations, 
with at least one area composed of a mixture of blasts and 
lymphocytes and/or myeloid cells (Fig 1). The majority (3  7/ 
52) of the biphenotypic cases had uniform light scatter 
populations of blasts easily separated from non-blast popula- 
tions. The excluded group showed more variable light scatter 
findings. Forty of the 79 excluded cases were deleted due to 
the finding of mature T-lymphocytes intermixed with the 
leukaemic blasts in the same light scatter population: 11 
cases were excluded based on myeloid cell contamination 
with lymphoid blasts. These cases demonstrating a mixture of 
blasts and mature lymphoid or myeloid elements could have 
been called biphenotypic if only percentages ofpositivity were 
considered; for example, T-lymphocytes plus myeloblasts 
could be mistakenly called T-lymphoid antigen-positive AML. 
The remaining cases were excluded based on the failure of the 
histogram analysis program to calculate percentages of 
positivity that reflected the separation of true staining from 
non-specific background staining based on subjective histo- 
gram evaluations. 
The annual frequency of biphenotypia was consistent over 
the first 5 years of the study (0.5-8.0%), but increased to 
13%ofall acuteleukaemiasduring 1990(P>0.05). 21/299 
(7.0%) acute myelogenous leukaemia (AML) cases, diag- 
nosed by FAB criteria, expressed a lymphoid-associated 
marker. These 21  cases of AML included six with the 
morphologic diagnosis of FAB-M2. three with FAB-M3, four 
with FAB-M4, five with FAB-M5, and three cases were CML 
in myeloid blast crisis. 30/447 (6.9%) acute lymphoblastic 
leukaemia (ALL) cases, diagnosed morphologically, 
expressed myeloid-associated marker(s) by flow cytometry. 
One case of chronic myelogenous leukaemia (CML) in 
lymphoid blast crisis was included in the biphenotypic ALL 
subgroup. One additional ALL case was also identified that 
expressed both B- and T-cell-associated antigens, but no 
myeloid antigens. 
Deniographic 
Table I summarizes the age distribution and clinical presen- 
tation of the biphenotypic AML and ALL groups. The majority 
of biphenotypic leukaemias in childhood had ALI, morpho- 
logy while the majority of adult biphenotypic leukaemias 
were diagnosed as AML. All 11 cases of acute biphenotypic 
leukaemia in relapse were ALL by FAB criteria. Ten of these 
11 were initially &cell precursor ALL, while one case was 
initially diagnosed as a T-ALL. No aberrant myeloid reactivity 
was immunologically evident in any of these 11 cases at the 
time of initial presentation. 
Lymphoid antigen-positive A ML 
The diagnosis of AML was confirmed by the predominant 
immunophenotypic expression of myeloid-associated anti- 
gens. All 2 1 cases of biphenotypic leukaemia morphologi- 
cally classified as AML (lymphoid antigen-positive AML) 
expressed CD13 ( n = 1 8 ) ,  CD33 (n=16) (Fig 2A). and/or 
CD14 (n= 7) and were further subgrouped into CD2-positive 
AML ( n  = 11 cases), CDl9-positive AML (n= 8 cases), and 
CD20-positive AML (n= 2 cases) (Table 11). It is of interest to 
note that the FAB diagnoses in the CD2-positive AML group 
included six cases with a monocytic component (FAB-M4 or 
FAB-MS), two acute promyelocytic leukaemias (FAB-MS), 
and three CML cases in myeloid blast crisis. In contrast, six of 
the eight CD19-positive AML group were FAB-M2. The per 
cent positivity of CD2, CD19 and CD20 in these lymphoid 
antigen-positive AML cases clearly indicated that a signifi- 
cant number of the leukaemic cells expressed these antigens. 
However, it can also be seen from these percentages (Table 11) 
that not every single leukaemic cell within a case co- 
expressed detectable myeloid- and lymphoid-associated anti- 
gens. This implies that either various immunologic subclones 
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Table 111. Myeloid antigen-positive ALL (n= 31). 
CD33+ only CD13+/CD33+ C D l l h +  CD13+ only CD14+ CD2+ 
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2 2 0 
9 3 3 
0 I 1 7 
5 4 2 
3 1 2 
1 0 0 
21-8711 7-58 23-56 29-44 
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Fig 2. ( A )  Single-parameter fluorescence histograms of CD2. CD13. CD3 3, and mouse isotype-matched negative control antibody in a case of 
CD2 + AML. (B) Single-parameter fluorescence histograms of CD13. CD33, CD10, CD19, CD20, and mouse isotype-matched negative control 
antibody in a CDl3/CD33 +ALL. (C) Single-parameter fluorescence histograms of CD33, CD19, CD22, and mouse isotype-matched negative 
control in a CD33 +ALL. The percentage of positive-staining cells is shown to the right of the histogram. 
were present, some biphenotypic and some not, or that the 
lymphoid-associated antigen was too weakly expressed in 
some of the leukaemic cells to be detected beyond background 
staining. 
Myeloid antigen-positive ALL 
The 31 cases of biphenotypic ALL (Table 111) included 26 
cases of B-precursor ALL, expressing CD10, CD19, CD20 
and/or CD22, and five cases which had T-cell antigen 
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Classification n Median Range Classification n Median Range P$ 
CD19+AML 8 59 52-65 B-pre ALLt 253 75 30-130 <0.01 
CD2’AML 11 73 65-80 T-ALL 26 97 72-126 <0.00 
CD13+ALL 13 56 31-67 AML 196 76 51-118 <0.01 
CD33+ALL 20 47 32-61 AML 195 76 47-116 <0.01 
* MCFI = mean channel fluorescence intensity. 
t B-pre ALL = B-precursor ALL. 
$ Student t test analysis. 
Ly+ AML 
My+ALL 
- I  
Normal Hyperdlploid Hypodiploid Structural 
CYTOGENETIC FINDINGS 
Fig 3. Bar graph showing distribution of general cytogenetic 
abnormalities in lymphoid antigen-positive AML (Ly + AML) and 
myeloid antigen-positive ALL (My + ALL) cases. 
Abnormalities 
expression. The B-precursor ALL cases were further subclas- 
sified into CD13-positive/CD33-positive ALL ( n  = 9 cases) (Fig 
2B), CD33 only-positive ALL (n=9  cases) (Fig 2C), CDllb- 
positive ALL (n=3  cases), CD13 only-positive ALL (n=3  
cases) and C14-positive ALL ( n  = 1 case). One B-precursor 
ALL case co-expressed the T-cell-associated antigen, CD2. 
Fluorescence intensitg 
Table IV compares the median fluorescence intensity (FI) of 
the aberrant lymphoid or myeloid marker in the biphenotypic 
leukaemias to the median FI of that same marker expressed in 
non-biphenotypic acute leukaemia. The FI of CD2, CD19, 
CD13 and CD33 in the biphenotypic leukaemias was signifi- 
cantly less (2-3 times dimmer) than the FI of these antigens 
in the corresponding non-biphenotypic leukaemias (T-ALL, 
%precursor ALL, and AML, respectively). 
CD34 expression 
The CD34 antigen, which can be identified in haematopoietic 
progenitor cells, i s  a characteristic marker of cells in the 
earliest stages of lymphoid and haematopoietic development 
(Civin et aI, 1987). Expression of the CD34 epitope on 
leukaemic cells suggests that malignant transformation 
occurred at an early stage of haematopoietic development. 
Conversely, the lack of expression may reflect transformation 
later in ontogeny. We thus evaluated CD34 expression in the 
biphenotypic acute leukaemias to determine whether these 
cases were indeed more ‘primitive’ (i.e. having CD34 ex- 
pression) than non-biphenotypic acute leukaemias diag- 
nosed in our laboratory. 
CD34 expression was significantly higher in biphenotypic 
leukaemias than in non-biphenotypic leukaemias. 3 1/42 
(74%) cases evaluated were CD34-positive. In contrast, 48% 
of all non-biphenotypic acute leukaemias from our labora- 
tory expressed CD34 (P<0.05). 16/19 (84%) lymphoid 
antigen-positive AML and 15/23 (65%) myeloid-antigen- 
positive ALL cases were positive for CD34. This compares 
with49XofAML (P<O.O5)  and46%ofALL(P<O.O5) cases 
expressing CD34 in the non-biphenotypic acute leukaemia 
group analysed in our laboratory. No difference in CD34 
antigenicity was seen among the various age groups or 
between de novo and relapse presentations. 
Cytogenetics 
Cytogenetic analysis was carried out in 42/52 (81%) of the 
biphenotypic acute leukaemia cases: these included 16  cases 
of AML and 26 cases of ALL. A normal, 46,XX female or 
46,XY male karyotype was found in 11/42 (26%) of the 
biphenotypic cases, including 2/16 (12%) AMLs and 9/26 
(3 5%) ALLs. A clonal abnormality was found in 31/42 (74%) 
cases, including hypodiploidy, hyperdiploidy, and structural 
abnormalities (Fig 3). These chromosomal abnormalities 
were found in both ALLs and AMLs in a distribution roughly 
similar to that found in acute non-biphenotypic leukaemias. 
Fig 4 and Table V demonstrate that a relatively limited 
number of cytogenetic aberrations were evident in the 
lymphoid antigen-positive AML group. Several of the chro- 
mosomal abnormalities found in this group were classical 
AML-associated translocations (Arthur et al, 1989: 
LeBeau, 1990). These included: six t(8;21)(q22:q22); 
three t(9;22)(q34;qll) (Philadelphia chromosome): two 
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Pig 4. Bar graph showing distribution of 
specific cytogenetic abnormalities for each 
chromosome in lymphoid antigen-positive AML 
(Ly +AML) and myeloid antigen-positive ALL 
CHROMOSOME # (My+ALL). 
Table V. Cytogenetic findings in lymphoid antigen-positive AML. 
Karyotype FAB D/R/BC* 





















CD19fAML (n= 7) 46,XY,t(8:21)(q22:q22) M2 D 
47.XX.t(8;21)(q22;q22). + 18,de1(9)(ql3:22) M2 D 
46,XX.t(8:21)(q22;q22) M2 D 
46.XY.t(8;2l)(q22:q22) M2 D 
46,XY,t(8:21 )(q22:q22 ).de1(9)(q22) M2 D 
46,XX.t(8;21)(q22:q22).t(l:l 5)(p15:q22).t(7;9)(p13;q22) M2 D 
46.XX M5 D 
CD2O + AML (11 = 1 ) 46,XY ,t(2; 1 l),del( 5 )(q) MS D 
* D = d~ novo: R =relapse: BC = blast crisis. 
acute promyelocyte leukaemias (FAB-M3) with a 
t( l5;  17)(q22:q21): one translocation involving 1 lq23: one 
acute myelomonocytic leukaemia with eosinophilia (FAB- 
M4e) having an inv(16)(p13q22): one trisomy 8; and one 
case of 5q-. Interestingly, all six t(8:21) cases expressed 
CD19 as the aberrant lymphoid-associated antigen. No 
typical ALL-associated translocations were identified. 
The myeloid antigen-positive ALLs, in contrast to the AML 
group, showed a wide range of chromosomal abnormalities 
affecting multiple chromosomes (Fig 4 and Table VI). Tri- 
somy 2 1 was identified in four cases: in only one of these cases 
did the patient have Down's syndrome. Other common 
abnormalities included: three t(9;22) (Philadelphia chromo- 
some); three with trisomy 8: three with translocations 
involving 3q2 1: three cases involving 17s; and two 1 lq2 3 
translocations, as well as several others. It is interesting to 
note that some of these abnormalities such as trisomy 21, 
trisomy 8, and translocations involving chromosomes 3q2 1 
or 17q. are more commonly found in myeloid processes than 
in ALL (Arthur et al, 1989: LeBeau et u I ,  1990). However, 
there were too few cases in this study to permit determination 
of statistical significance. 
DISCUSSION 
In this study we have retrospectively analysed the immuno- 
phenotype of 746 cases of acute leukaemia studied in our 
laboratory. From this cohort, we have identified 52 acute 
biphenotypic leukaemias (7.0%), with lymphoid antigen- 
positive AML and myeloid antigen-positive ALL diagnosed in 
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Table VI. Cytogenetic findings in myeloid antigen-positive ALL. 
CD33+ALL ( n = 1 0 )  
CD13+/33+ALL (n=7) 
CDllb+ALL (n=3)  
CD14+ALL ( n = l )  
CD2 +ALL ( n =  1) 
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* B = B-precursor ALL T = T-ALL. 
t D = de riovo: R =relapse: BC = blast crisis. 
roughly the same percentage of cases. The difficulty in 
evaluating these results is that the reported frequency of 
biphenotypic leukaemia in the literature has varied from less 
than 1% of acute leukaemia cases in some studies to almost 
50% of acute leukaemia cases in others (Perentesis et al, 
1983: Mirro et al, 1985, 1986; Stass &Mirro, 1985; Drexler 
et al, 1986; Campos et al, 1987; Cross et al, 1988; Schmitt- 
Graff et al, 1988; Del Vecchio et al, 1989; Kaplan et a/, 1989; 
Rkashi et a/, 1990; Gerhartz & Schnitzer, 1990; Sulak et ul, 
1990). This widely variably incidence range cannot be 
rationally explained solely on the basis of clinical variability 
between different population groups. Indeed, this variability 
along with the lack of consensus as to clinical or biological 
significance of biphenotypia in acute leukaemia is undoub- 
tedly due to several contributing factors: the use of inconsis- 
tent and variable diagnostic criteria, the inevitable (but 
frequently ignored) subjectiveness of immunophenotypic 
interpretation, and the lack of a standardized and uniform 
panel of monclonal antibodies utilized in immunophenotypic 
analyses (Gale & Ben-Bassat, 1987: Maitreyan & Gale, 
1989). 
The lack of an accepted, standardized, and reproducible 
method of immunophenotypic analysis and the subjective- 
ness of flow cytometric interpretation are probably the 
biggest contributors to the inconsistency of diagnosing 
biphenotypia. The single diagnostic criterion listed in several 
reports has been the simple requirement that only 20% or 
30% of cells needs to express either lymphoid- or myeloid- 
associated antigens to meet the definition of biphenotypia 
(Perentesisetal, 1983;Mirroetal, 1985,1986; Stass&Mirro, 
1985; Campos et al, 1987; Cross et al, 1988: Schmitt-Graff et 
al, 1988;DelVecchioet al, 1989; Akashietal, 1990; Gerhartz 
& Schnitzer. 1990; Sulak et al, 1990). The use of this limited 
definition fails to recognize the problems associated with 
analysing blood or bone marrow specimens that inevitably 
contain a mixture of leukaemic blasts and mature lympho- 
cytes or differentiating myeloid (leukaemic or normal) cells. 
In this same context, it must also be remembered that the 
patient specimen received for flow cytometric analysis may 
contain a different mixture of blasts and normal blood/bone 
marrow elements than the specimen received for morpho- 
logic review. We have tried to overcome this variability by 
examining the morphology of each specimen received in the 
laboratory, as well as preparing and examining a cytocentri- 
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Fortunately, the development of the cluster designation (CD) 
system for categorizing monoclonal antibody reactivity pro- 
vides a more consistent method of evaluating and comparing 
antibodies (Reinherz, 1986; McMichal, 1987; Knapp, 1989). 
In addition, it is also important to consider the possibility that 
many of the MoAbs used diagnostically may not be lineage- 
spec@, but rather lineage-associated (Reinherz, 1986: Cam- 
pos et a1, 1987; McMichal, 1987; Hanson & Gajl-Peczalska. 
1988; Knapp, 1989). In other words, insufficient knowledge 
about the specificity of monoclonal antibody reactivity may 
prevent accurate lineage determination (Greaves et ul, 1986). 
In this study, biphenotypia was based on CD2, CD19 or 
CD20 expression in AML and CDllb, CD13, CD14 and/or 
CD33 expression in ALL. These antibodies were chosen based 
on two factors: one, they have historically been considerd as 
lineage-restricted: and two, they have been used as evidence 
of biphenotypia in previous studies. These arbitrary designa- 
tions have been determined by time-honoured, single-colour 
studies of haematopoietic development in both normal bone 
marrows and in acute leukaemias and may not survive the 
test of time as more sophisticated flow cytometric studies 
emerge. Reports have now described CD2 expression in fetal 
non-T-cells (Uckun et al. 1989), CD19 and CD20 in myeloid 
cells (Campos et al, 1987; Gerhartz & Schnitzer, 1990), and 
CD14 in significant numbers of malignant lymphomas 
(Medeiros et al, 1991). Also, it is well known that CDllb is 
expressed in both lymphoid and myeloid cells (Hanson & Gajl- 
Peczalska, 1988). Though reactivity with these antibodies 
has been interpreted in the past as evidence of either 
lymphoid or myeloid lineage, recent studies suggest that one 
cannot assume absolute lineage-specificity for these anti- 
bodies. Therefore, the premise that the expression of CD2. 
CD19 and CD20 in AML or CD14 and CDllb in ALL 
represents evidence of biphenotypia may not be accurate. 
Only CD13 and CD33 have continued to be considered as 
myeloid-specific antigens. Further studies of normal mar- 
rows, fetal and adult, must be performed using multi- 
parameter analysis to fully assess the normal immunologic 
sequence of haematopoietic development (Haynes et al, 
1988; Uckun et al, 1989: LeBien et al, 1990; Grumayer et 01, 
1991). Only with this knowledge will we be able to truly 
assess biphenotypism 
Previous studies of biphenotypic leukaemia have suggested 
that these leukaemias may arise by malignant transforma- 
tion of a pluripotent stem cell. The finding of a significantly 
greater percentage of biphenotypic cases with CD34 ex- 
pression, compared to non-biphenotypic cases, supports the 
concept that this transformation process occurs at a step close 
to the haematopoietic progenitor cell. Similar conclusions 
have also been drawn from cytogenetic studies of acute 
leukaemia. Acute leukaemias that have either the 
t( 9 : 2 2)( q3 4:q 1 1 ) (Philadelphia chromsome) (Hirsch-Gins- 
berg et al, 1988; Hayashi et al, 1990b) or translocations 
involving l l q 2 3  (Childs et al, 1988; Hayashi et al, 1990b) 
have been shown to have a high incidence of biphenotypic 
expression. These cytogenetic abnormalities are associated 
with both lymphoid and myeloid leukaemias suggesting that 
they reflect stem cell transformations. This ‘dual’ association 
may account for the ‘promiscuous’ lymphoid/myeloid immu- 
fuge preparation of the gradient-separated cells. This latter 
methodology allowed us to correlate directly the morphologic 
features of the specimen with the subsequent light scatter 
characteristics to permit the establishment of accurate 
electronic ‘gates’ around the leukaemic cells of interest. By 
ignoring these morphologic correlates, one may interpret the 
flow cytometric results erroneously if they are based solely on 
orthogonal and forward light scatter characteristics. Normal 
lymphocytes, erythroid precursors, or differentiating myeloid 
cells may fall into the same gated area as the leukaemic blasts 
and must be distinguished from them and excluded to 
accurately interpret the immunophenotypic results. 
The morphologic features, the cytocentrifuge preparation 
of gradient-separated cells, the percentage of blasts present, 
the light scatter characteristics, and the fluorescence histo- 
gram patterns, etc., all potentially provide significant diag- 
nostic information that far outweighs the diagnostic signifi- 
cance of arbitrary percentages of stained cells. Although it is 
likely that previous studies of biphenotypia have informally 
used such subjective criteria, the failure to fully document 
and discuss these diagnostic criteria has presented the 
development of a uniform and consistent method of analys- 
ing and diagnosing biphenotypic leukaemias. Our approach 
may not necessarily be the ideal method, but it does provide a 
starting point for more accurate comparison. 
Two-colour immunofluorescence has rapidly become the 
method of choice for analysing clinical specimens (Shapiro, 
1988: Uckun et al, 1989). This is an ideal method for 
demonstrating simultaneous expression of antigens, such as 
in biphenotypia, especially when leukaemic blasts are inter- 
mixed with normal or differentiating cells. Because our study 
was retrospectively based over a 6-year period, we were 
restricted to using single-colour immunophenotyping 
results. It is presumptuous to assume that this latter tech- 
nique is outdated and undesirable and that two-colour 
analysis is the absolute gold standard. Although determina- 
tion of dual staining by single-colour analysis does require 
rigorous criteria, the use of two-colour immunofluorescence 
staining does not preclude the necessity of utilizing morpho- 
logic, light scatter, and fluorescence histogram data when 
interpreting results. Indeed, the interpretation of flow cyto- 
metric ‘positivity’ with two-colour staining should be based 
on the same strict criteria that we have used in this study. 
Moreover, the use of directly conjugated MoAbs in two- 
colour analysis may decrease sensitivity, potentially up to 5- 
6-fold (Shapiro, 1988). The fluorescence intensity of the 
aberrantly expressed antigens was 2-3 times dimmer in the 
biphenotypic leukaemias. theoretically making them more 
difficult to detect by direct-staining methods. In addition, 
two-colour staining requires adjusting colour compensation 
and setting quadrant gates, adding further subjectivity to the 
flow cytometric process. In spite of these considerations, the 
evolution of two-colour immunofluorescence potentially will 
promote greater specificity of immunophenotyping and a 
better understanding of normal haematopoietic develop- 
ment. 
Another important factor that has contributed to the 
confusion in the literature about biphenotypia has been the 
use of widely variable panels of monoclonal antibodies. 
58 
nophenotype frequently found in these leukaemias. Cytoge- 
iietic results from our study indeed did show that nine of the 
3 1 clonal karyotypes contained the Philadelphia chromo- 
some or an l l q 2 3  translocation, confirming that these 
cytogenetic translocations are commonly found in bipheno- 
typic leukaemia. Since both of these chromosomal abnor- 
malities have clearly been shown to be independent, high- 
risk factors for acute leukaemia patients (Bloomfield et al, 
1989), cytogenetic findings must also be considered when 
determining whether or not biphenotypic expression has any 
independent clinical significance in patients with acute 
leukaemia. 
Other chromosomal aberrations identified in the bipheno- 
typic leukaemias from our study also provoked some interest- 
ing speculation. Within the lymphoid antigen-positive AML 
group, classical myeloid-associated translocations, including 
t(8:21), t(15:17), inv (16), trisomy 8, 5q-, or t(9;22), were 
identified in 13 of the 14 AML cases with cytogenetic 
abnormalities (Arthur et al, 1989: LeBeau, 1990). These 
translocations or deletions are typically associated with acute 
myelogenous leukaemias showing distinct morphologic and 
immunologic evidence of myeloid differentiation. 
What then do the lymphoid-antigen-positive AML cases 
represent? The identification of these translocations so often 
associated with a myeloid phenotype, the morphologic 
evidence of differentiation (FAB-M2, M3, M4), and the 
probable lack of lineage-specificity of CD2, CD19 and CD20. 
raise the distinct possibility that these cases are simply cases 
of AML that are expressing uncommon ‘lymphoid/myeloid’- 
associated antigens. Ball et a1 (1991) also identified typical 
myeloid-associated translocations in lymphoid antigen-posi- 
tive AML and showed that these leukaemias have a prognosis 
similar to or better than other AMLs. Thus, it may not be valid 
to look at this group of leukaemias as being truly biphenoty- 
pic. At the minimum, there is certainly the need to search for 
lymphoid-associated antigens on normal myeloid progenitor 
cells. 
The cytogenetic findings in the myeloid antigen-positive 
ALL group, however, suggested a very different conclusion 
and raise some interesting diagnostic and biological ques- 
tions. Some lymphoid-associated chromosomal abnormali- 
ties that can be seen in lymphoid leukaemias, such as 
hyperdiploidy, 6q-, t(9;22), and l l q23 ,  were identified in 
6/17 cases (Bloomfield et al, 1989). It was intriguing, 
however, to recognize several translocations within this 
myeloid antigen-positive ALL group that are more commonly 
associated with myeloid-type processes (Arthur et al, 1989: 
LeBeau, 1990). For example, trisomy 21  is a common finding 
in acute megakaryoblastic leukaemias (Johanson et al, 
1990). Trisomy 8 is commonly found not only in acute 
myelogenous leukaemias, but also in myelodysplastic syn- 
dromes (LeBeau, 1990). Translocations involving 3q2 1 have 
been reported in myeloid leukaemias with abnormal mega- 
karyopoiesis (Bernstein et al, 1982). The finding of these 
chromosomal abnormalities in cases with ALL morphology 
suggests that these leukaemias did indeed have dual-lineage 
heritage. As is summarized in a recent study (Drexler et al, 
1991 ), adults with myeloid antigen-positive ALL may have a 
worse prognosis than those with conventional ALL. While 
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biphenotypia is generally defined in immunologic terms, 
cytogenetic data may also be valuable when determining the 
cellular lineage of a leukaemic proliferation. 
In summary, biphenotypic leukaemia continues to pro- 
voke more questions than answers. Some of these questions 
may be answered as more uniform laboratory diagnostic 
criteria are used and the spectrum of monoclonal antibody 
reactivity is more completely understood and standardized. 
Leukaemias with the Philadelphia chromosome or 1 lq23 
translocations have clearly been associated with bipheno- 
typic processes (Childs et al, 1988: Hirsch-Ginsberg et al, 
1988: Hayashi et al, 1990b). Identification of other immuno- 
logic and cytogenetic subgroups will be essential in further 
characterizing and understanding these intriguing leukae- 
mias and the cellular counterparts from which they arise. 
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